Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PET imaging of osteosarcoma.

Winfried Brenner1, Karl H Bohuslavizki, Janet F Eary

  • 1Division of Nuclear Medicine, University of Washington Medical Center, Seattle, Washington 98195-6113, USA. winbren_2000@yahoo.com

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|June 7, 2003
PubMed
Summary

Positron Emission Tomography (PET) imaging, particularly with (18)F-FDG, shows promise for osteosarcoma diagnosis, staging, and monitoring treatment response. Further research is needed to establish its full clinical utility in osteosarcoma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantification of overall tumor burden using longitudinal magnetic resonance imaging improves response assessment in orthotopic murine hepatocellular carcinoma models.

Scientific reports·2026
Same author

Radioactive Gold Isotopes in the Era of Theranostics: Medical Potential of ¹⁹⁸Au and ¹⁹⁹Au Radioisotopes.

Nuklearmedizin. Nuclear medicine·2026
Same author

Optimizing PET/CT protocols: is 60-minute [18 F]F-FDG uptake sufficient for cardiac sarcoidosis?

EJNMMI research·2026
Same author

Synthesis and in vitro characterization of [<sup>198</sup>Au]Auranofin.

EJNMMI radiopharmacy and chemistry·2025
Same author

Spatial tumour characteristics as an indirect marker of metabolic dysregulation: evaluation for non-invasive IDH-genotyping of glioma using hybrid [18 F]FET-PET/MRI.

European journal of nuclear medicine and molecular imaging·2025
Same author

[<sup>18</sup>F]FDG PET/CT for treatment monitoring and prediction of progression in retroperitoneal fibrosis.

European journal of nuclear medicine and molecular imaging·2025

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiology

Background:

  • Positron Emission Tomography (PET) imaging has gained acceptance in tumor imaging over the past decade.
  • (18)F-FDG PET is approved and reimbursed for various cancers, including lung, melanoma, lymphoma, head and neck, brain, esophageal, and colorectal cancers.
  • Neoadjuvant chemotherapy in osteosarcoma has improved survival, increasing the need for advanced imaging in staging, grading, treatment evaluation, and recurrence detection.

Purpose of the Study:

  • To critically summarize the literature on PET imaging in osteosarcoma patients.
  • To evaluate PET imaging's role in diagnosis, staging, therapy monitoring, and follow-up.
  • To outline potential and probable indications for PET imaging in osteosarcoma.

Main Methods:

Related Experiment Videos

  • Review of available literature on PET imaging in osteosarcoma.
  • Focus on clinically used tracers: (18)F-FDG and (18)F-fluoride ion.
  • Analysis of studies concerning diagnosis, staging, therapy monitoring, and follow-up.

    • Main Results:

    • PET imaging, especially (18)F-FDG, is being investigated for its utility in osteosarcoma.
    • The review summarizes current findings regarding PET's application in various aspects of osteosarcoma management.
    • Potential and probable clinical indications for PET in osteosarcoma are identified.

    Conclusions:

    • PET imaging holds potential for improving osteosarcoma management.
    • Current clinical trial data is limited by small patient numbers.
    • Larger, prospective studies are required to fully determine the utility of PET in osteosarcoma.